Meeting
2024 ASCO Gastrointestinal Cancers Symposium
First-308: Phase III study of tinengotinib versus physician's choice in patients with FGFR-altered, chemotherapy- and FGFR inhibitor–refractory/relapsed cholangiocarcinoma.
Authors
Milind M. Javle
Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX
Milind M. Javle , Lorenza Rimassa , Lipika Goyal , Amit Mahipal , Christos Fountzilas , Chih-Yi Liao , Meredith Pelster , Parvez Mantry , John A Bridgewater , Antoine Hollebecque , Timon Vandamme , Lucjan Wyrwicz , Peng Peng , Caixia Sun , Katie Hennessy , Hui Wang , Ximei Fu , Frank Wu , Jean Fan , Do-Youn Oh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05948475
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr TPS575)
DOI
10.1200/JCO.2024.42.3_suppl.TPS575
Abstract #
TPS575
Poster Bd #
P4
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Indirect treatment comparison of futibatinib with chemotherapy and pemigatinib in cholangiocarcinoma with FGFR2 fusions/rearrangements.
First Author: Mitesh J. Borad
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Phase II study of FGFR1-3 inhibitor tinengotinib as monotherapy in patients with advanced or metastatic cholangiocarcinoma: Interim analysis.
First Author: Milind M. Javle
Poster
2020 Gastrointestinal Cancers Symposium
A phase III study of futibatinib (TAS-120) versus gemcitabine-cisplatin (gem-cis) chemotherapy as first-line (1L) treatment for patients (pts) with advanced (adv) cholangiocarcinoma (CCA) harboring fibroblast growth factor receptor 2 (FGFR2) gene rearrangements (FOENIX-CCA3).
First Author: Mitesh J. Borad
Poster
2019 Gastrointestinal Cancers Symposium
Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement.
First Author: Tanios S. Bekaii-Saab